- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Enoxaparin Fails to Reduce VTE risk among Hospitalized Older Adults: NEJM
In a recent trial, low-molecular-weight heparin (enoxaparin) failed to demonstrate a reduction in the risk of symptomatic VTE within one month through the use of enoxaparin in medically ill, hospitalized older adults. The findings were published in NEJM Evidence.
The trial, which enrolled patients over the age of 70, aimed to determine whether enoxaparin could effectively reduce the incidence of VTE in this high-risk population. Conducted at 47 centers, the trial was prematurely discontinued in September 2020 due to drug supply issues, after five years of enrollment. By that time, 2,559 patients had been randomly assigned to receive either enoxaparin or a placebo for a period of 6 to 14 days. The median age of the participants was 82 years, with 60% being female.
The primary efficacy outcome measured was the cumulative incidence of symptomatic VTE, including distal or proximal deep vein thrombosis and fatal or nonfatal pulmonary embolism, at 30 days. The primary safety outcome assessed was major bleeding. Secondary outcomes, including efficacy and safety measures, were evaluated at the 90-day mark.
Among the intention-to-treat population, the trial results indicated that the primary efficacy outcome occurred in 1.8% of patients in the enoxaparin group (22 out of 1,278) and 2.2% of patients in the placebo group (27 out of 1,263). The difference in cumulative incidence between the two groups was not statistically significant, with a cumulative incidence difference of -0.4 percentage points and a confidence interval of -1.5 to 0.7. The time to VTE also did not differ significantly between the groups.
Regarding safety outcomes, the incidence of major bleeding was similar between the enoxaparin group (0.9%) and the placebo group (1.0%). At the 90-day follow-up, there were 14 cases of symptomatic pulmonary embolism in the enoxaparin group and 25 cases in the placebo group. Unfortunately, all 39 cases of pulmonary embolism resulted in hospital readmission and/or death, with five deaths attributed to pulmonary embolism in the enoxaparin group and 11 deaths in the placebo group.
Source:
Mottier, D., Girard, P., Couturaud, F., Lacut, K., Le Moigne, E., Paleiron, N., Guellec, D., Sanchez, O., Cogulet, V., Laporte, S., Marhic, G., Mismetti, P., Darbellay Farhoumand, P., Cuvelier, C., … Le Gal, G. (2023). Enoxaparin versus Placebo to Prevent Symptomatic Venous Thromboembolism in Hospitalized Older Adult Medical Patients. In NEJM Evidence. Massachusetts Medical Society. https://doi.org/10.1056/evidoa2200332
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751